General Info

Cytokinetics is a biopharmaceutical company focused on the discovery, development and commercialization of novel small molecule drugs that specifically target the cytoskeleton. The company s focus on the cytoskeleton enables it to develop novel and potentially safer and more effective classes of drugs directed at treatments for cancer, cardiovascular disease and other diseases. The company has developed a cell biology driven approach and proprietary technologies to evaluate the function of many interacting proteins in the complex environment of the intact human cell. The approach has yielded novel small molecule drug candidates that are in clinical development and two novel small molecule potential drug candidates in development, one in cancer and the other for heart failure. Its most advanced drug candidate, ispinesib is the subject of a Phase II clinical trials program designed to evaluate its effectiveness in many different types of cancer. Cytokinetics is headquartered in South San Francisco.